HuGE Literature Finder
Records 1-30
|
Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation.
Basic & clinical pharmacology & toxicology 2020 Sep . Nakagawa Junichi, Kinjo Takahiko, Iizuka Mei, Ueno Kayo, Tomita Hirofumi, Niioka Takeno |
|
ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone.
Progress in neuro-psychopharmacology & biological psychiatry 2020 Jul 110042. Ganoci Lana, Trkulja Vladimir, Živkovic Maja, Božina Tamara, Šagud Marina, Lovric Mila, Božina Na |
|
Representation of CYP3A4, CYP3A5 and UGT1A4 Polymorphisms within Croatian Breast Cancer Patients' Population.
International journal of environmental research and public health 2020 May 17 (10): . Bojanic Kristina, Kuna Lucija, Bilic Curcic Ines, Wagner Jasenka, Smolic Robert, Kralik Kristina, Kizivat Tomislav, Ivanac Gordana, Vcev Aleksandar, Wu George Y, Smolic Marti |
|
Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care.
Journal of thrombosis and thrombolysis 2019 Sep . Gulilat Markus, Keller Denise, Linton Bradley, Pananos A Demetri, Lizotte Daniel, Dresser George K, Alfonsi Jeffrey, Tirona Rommel G, Kim Richard B, Schwarz Ute |
|
Genetic Variation in Steroid and Xenobiotic Metabolizing Pathways and Enterolactone Excretion Before and After Flaxseed Intervention in African American and European American Women.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2019 Feb 28 (2): 265-274. Chang Huiru, Yao Song, Tritchler David, Hullar Meredith A, Lampe Johanna W, Thompson Lilian U, McCann Susan |
|
Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patients.
Pharmacogenomics 2018 Sep . Sim Sarah, Bergh Jonas, Hellström Mats, Hatschek Thomas, Xie Hanji |
|
Detection of Cytochrome P450 Polymorphisms in Breast
Cancer Patients May Impact on Tamoxifen Therapy
Asian Pacific journal of cancer prevention : APJCP 2018 Feb 19 (2): 343-350. Thota Kanakaiah, Prasad K, Basaveswara Rao Mandava |
|
The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers.
Journal of clinical pharmacy and therapeutics 2017 Feb . Xiang Q, Li C, Zhao X, Cui Y |
|
Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients.
Breast cancer (Dove Medical Press) 2017 9 249-256. Charoenchokthavee Wanaporn, Areepium Nutthada, Panomvana Duangchit, Sriuranpong Viro |
|
Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes.
Anticancer research 2017 05 37 (5): 2633-2639. Angelini Silvia, Botticelli Andrea, Onesti Concetta Elisa, Giusti Raffaele, Sini Valentina, Durante Valeria, Strigari Lidia, Gentile Giovanna, Cerbelli Bruna, Pellegrini Patrizia, Sgroi Valentina, Occhipinti Mario, DI Pietro Francesca Romana, Rossi Alessandro, Simmaco Maurizio, Mazzuca Federica, Marchetti Pao |
|
Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients: A hospital-based observational study.
Medicine 2016 Nov 95 (44): e5151. Tsuji Daiki, Ikeda Midori, Yamamoto Keisuke, Nakamori Harumi, Kim Yong-Il, Kawasaki Yohei, Otake Aki, Yokoi Mari, Inoue Kazuyuki, Hirai Keita, Nakamichi Hidenori, Tokou Umi, Shiokawa Mitsuru, Itoh Kunihi |
|
Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1.
Journal of clinical pharmacology 2016 May . Powers Jennifer L, Buys Saundra S, Fletcher Deborah, Melis Roberta, Johnson-Davis Kamisha, Lyon Elaine, Malmberg Elisabeth M, McMillin Gwendolyn |
|
ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen.
OncoTargets and therapy 2016 9 2121-9. Sensorn Insee, Sukasem Chonlaphat, Sirachainan Ekaphop, Chamnanphon Montri, Pasomsub Ekawat, Trachu Narumol, Supavilai Porntip, Pinthong Darawan, Wongwaisayawan Sansan |
|
Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment.
Breast cancer (Dove Medical Press) 2016 8 149-55. Charoenchokthavee Wanaporn, Panomvana Duangchit, Sriuranpong Virote, Areepium Nuttha |
|
Generalized Multifactor Dimensionality Reduction (GMDR) Analysis of Drug-Metabolizing Enzyme-Encoding Gene Polymorphisms may Predict Treatment Outcomes in Indian Breast Cancer Patients.
World journal of surgery 2015 Oct . Agarwal Gaurav, Tulsyan Sonam, Lal Punita, Mittal Balr |
|
Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy.
International journal of clinical pharmacology and therapeutics 2015 Sep . Zhou Xinna, Wang Xiaoli, Song Qingkun, Yang Huabing, Zhu Xishan, Yu Jing, Song Guohong, Di Lijun, Ren Jun, Shao Hong, Lyerly Herbert K |
|
Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy.
Clinica chimica acta; international journal of clinical chemistry 2014 Jul 434 21-8. Tulsyan Sonam, Agarwal Gaurav, Lal Punita, Mittal Balr |
|
Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach.
Gene 2014 Jun 543 (1): 69-75. Tulsyan Sonam, Chaturvedi Pankaj, Singh Abhishek Kumar, Agarwal Gaurav, Lal Punita, Agrawal Sushma, Mittal Rama Devi, Mittal Balr |
|
Comparative study of polymorphism frequencies of the CYP2D6, CYP3A5, CYP2C8 and IL-10 genes in Mexican and Spanish women with breast cancer.
Pharmacogenomics 2013 Oct 14 (13): 1583-92. Alcazar-González Gregorio Antonio, Calderón-Garcidueñas Ana Laura, Garza-Rodríguez María Lourdes, Rubio-Hernández Gabriela, Escorza-Treviño Sergio, Olano-Martin Estibaliz, Cerda-Flores Ricardo Martín, Castruita-Avila Ana Lilia, González-Guerrero Juan Francisco, le Brun Stéphane, Simon-Buela Laureano, Barrera-Saldaña Hugo Alber |
|
Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
Clinical pharmacokinetics 2013 Sep 52 (9): 751-62. Ogasawara Ken, Chitnis Shripad D, Gohh Reginald Y, Christians Uwe, Akhlaghi Fatem |
|
Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients.
Journal of cancer research and clinical oncology 2013 Mar 139 (3): 419-27. Tang Nelson L S, Liao Chen Di, Wang Xingyan, Mo Frankie K F, Chan Vicky T C, Ng Rita, Pang Elizabeth, Suen Joyce J S, Woo Jean, Yeo Winn |
|
Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen.
Pharmacogenomics and personalized medicine 2013 6 93-8. Sensorn Insee, Sirachainan Ekaphop, Chamnanphon Montri, Pasomsub Ekawat, Trachu Narumol, Supavilai Porntip, Sukasem Chonlaphat, Pinthong Daraw |
|
Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patients.
PloS one 2013 8 (7): e70183. Fernández-Santander Ana, Gaibar María, Novillo Apolonia, Romero-Lorca Alicia, Rubio Margarita, Chicharro Luis Miguel, Tejerina Armando, Bandrés Fernan |
|
The pharmacokinetics of letrozole: association with key body mass metrics.
International journal of clinical pharmacology and therapeutics 2012 Aug 50 (8): 557-65. Jin Seok-Joon, Jung Jin Ah, Cho Sang-Heon, Kim Un-Jib, Choe Sangmin, Ghim Jong-Lyul, Noh Yook-Hwan, Park Hyun-Jung, Kim Jung-Chul, Jung Jin-A, Lim Hyeong-Seok, Bae Kyun-Se |
|
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.
Breast cancer research and treatment 2012 Jul 134 (1): 401-10. Hertz Daniel L, Motsinger-Reif Alison A, Drobish Amy, Winham Stacey J, McLeod Howard L, Carey Lisa A, Dees E Clai |
|
Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.
Cancer chemotherapy and pharmacology 2012 May 69 (5): 1221-7. Kim Kyu-pyo, Ahn Jin-Hee, Kim Sung-Bae, Jung Kyung Hae, Yoon Dok Hyun, Lee Jung Shin, Ahn Sei-Hy |
|
Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.
European journal of clinical pharmacology 2012 Apr 68 (4): 389-95. Afsar Nasir Ali, Ufer Mike, Haenisch Sierk, Remmler Cornelia, Mateen Ahmed, Usman Ahmed, Ahmed Khwaja Zafar, Ahmad Hakimuddin Razi, Cascorbi Ingo |
|
Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients.
BMC medical genetics 2012 13 (1): 45. Seredina Tatyana A, Goreva Olga B, Talaban Valeria O, Grishanova Alevtina Yu, Lyakhovich Vyacheslav |
|
Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma.
Clinical pharmacology and therapeutics 2011 May 89 (5): 708-17. Mürdter T E, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, Fasching P A, Fehm T, , Eichelbaum M, Schwab M, Brauch |
|
Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients.
British journal of clinical pharmacology 2011 May 71 (5): 737-50. Lim Joanne S L, Chen Xiang A, Singh Onkar, Yap Yoon S, Ng Raymond C H, Wong Nan S, Wong Mabel, Lee Edmund J D, Chowbay Balr |
- Page last reviewed:Oct 1, 2020
- Page last updated:Sep 16, 2021
- Content source: